CRVS
CRVS clinical trials: Corvus Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Corvus Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 11
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
CRVS on the catalyst calendar · CRVS registry changes
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT03952078A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaCorvus Pharmaceuticals, Inc. · T-cell LymphomaActive, not recruitingCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1NCT07828860Safety and Efficacy of Soquelitinib in Adults With Hidradenitis SuppurativaCorvus Pharmaceuticals, Inc. · Hidradenitis Suppurativa (HS)RecruitingCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular...Corvus Pharmaceuticals, Inc. · Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecruitingCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2026ActualPhase 1NCT06345404Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe ADCorvus Pharmaceuticals, Inc. · Atopic DermatitisCompletedCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT07441395Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADCorvus Pharmaceuticals, Inc. · Atopic DermatitisRecruitingCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2022ActualPhase 1NCT03454451CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCorvus Pharmaceuticals, Inc. · Non-Small Cell Lung CancerCompletedCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2021ActualPhase 3NCT04734873CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 PatientsCorvus Pharmaceuticals, Inc. · Covid-19TerminatedCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 21, 2021ActualPhase 1NCT04280328Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple MyelomaCorvus Pharmaceuticals, Inc. · Multiple MyelomaCompletedCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2021ActualPhase 1NCT02655822Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCorvus Pharmaceuticals, Inc. · Renal Cell CancerCompletedCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2021ActualPhase 1NCT04464395Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 PatientsCorvus Pharmaceuticals, Inc. · COVID-19CompletedCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 20, 2017ActualPhase 1NCT03237988Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female SubjectsCorvus Pharmaceuticals, Inc. · Healthy SubjectsCompletedCRVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner